Interventional Cardiology
ISCHEMIA Trial 2ry Analysis | Patients with CCD and daily/weekly angina seem to benefit most from complete revascularization
26 Jul, 2023 | 13:33h | UTCComplete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentaries:
Complete Revascularization and Angina-Related Health Status – American College of Cardiology
More Angina Relief With Complete Revascularization in Stable CAD: ISCHEMIA – TCTMD
Related/Original Articles:
ISCHEMIA Trial: Initial Invasive vs. Conservative Strategy for Stable Coronary Disease
ISCHEMIA Trial: Management of Coronary Disease in Patients with Advanced Kidney Disease
Perspective | What does it mean to discover a coronary blockage?
26 Jul, 2023 | 13:31h | UTCChapter 1: What Does it Mean to Discover a Coronary Blockage? – By Dr John Mandrola
Chapter 2: On the meaning of a coronary blockage – By Dr John Mandrola
M-A | P2Y12 monotherapy after 1-3 months DAPT safely reduces bleeding in PCI patients with CAD and CKD
26 Jul, 2023 | 13:18h | UTCRelated:
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis – Nature Reviews Cardiology (if the link is paywalled, try this one)
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial – JAMA Cardiology (link to abstract – $ for full-text)
Consensus Paper | De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and PCI
24 Jul, 2023 | 13:08h | UTCDe-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis – Nature Reviews Cardiology (if the link is paywalled, try this one)
RCT | Half-dose Tenecteplase + later PCI if indicated seems to be viable option in older individuals when timely PCI is unavailable
21 Jul, 2023 | 13:36h | UTCHalf-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment–Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial – Circulation (link to abstract – $ for full-text)
Commentary on Twitter
In the #STREAMI-2 trial of older adults w/ early-presenting STEMI, half-dose tenecteplase w/ PCI if indicated comparable to primary PCI for ECG/angio endpoints and 30d clinical efficacy but w/ higher risk of ICH @Cardio_KULeuven @CVC_UAlberta @BaineyKevin https://t.co/zFE6C1U98n pic.twitter.com/noWWhJ6y9h
— Circulation (@CircAHA) July 18, 2023
Review | Guiding the use of invasive cardiac interventions in patients with advanced malignancies
17 Jul, 2023 | 13:23h | UTC
Review | Functional coronary angiography for the assessment of the epicardial vessels and the microcirculation
27 Jun, 2023 | 13:33h | UTC
Commentary on Twitter
🆕 STATE OF THE ART: Functional coronary angiography for the assessment of the epicardial vessels and the microcirculation by Faria D, et al. https://t.co/gMUMILNCdc angiography-for-the-assessment-of-the-epicardial-vessels-and-the-microcirculation pic.twitter.com/mSUihEZf78
— EuroIntervention (@EuroInterventio) June 20, 2023
M-A | Similar death rates in left main disease patients treated with PCI or CABG, both in patients with and without ACS
15 Jun, 2023 | 14:59h | UTCPercutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials – JAMA Cardiology (link to abstract – $ for full-text)
Commentary: CABG and PCI Comparable in ACS Patients With Left Main CAD – TCTMD
Consensus Statement | Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging
13 Jun, 2023 | 13:49h | UTCClinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group – Nature Reviews Cardiology (if the link is paywalled, try this one)
Commentary on Twitter
Check out our new Consensus Statement by @ProfDewey and the Quantitative Cardiovascular Imaging Study Group on the optimal use of imaging modalities to detect and assess coronary artery stenosis and atherosclerosis | https://t.co/WcKzwvE3UU pic.twitter.com/bipgb1zYuE
— Nature Reviews Cardiology (@NatRevCardiol) June 8, 2023
Consensus Paper | Applied coronary physiology for planning and guidance of percutaneous coronary interventions
30 May, 2023 | 11:58h | UTC
Review | Bail-out techniques in percutaneous intervention for Ellis Grade III coronary perforation in left main distal bifurcation lesions
29 May, 2023 | 10:51h | UTC
Commentary on Twitter
#Perforations of #LeftMainBifurcations can be fatal. Hemostasis & maintenance of flow in coronaries are critical. Covered stents can be life-saving.
➡️https://t.co/JkvBWzZFkJ @esbrilakis @GreggWStone @kleechuyMD pic.twitter.com/pXJpvyCnlC
— MyJSCAI (@MyJSCAI) April 20, 2023
SCAI Consensus Statement | Management of in-stent restenosis and stent thrombosis
22 May, 2023 | 13:41h | UTCNews Release: Guidance on management of in-stent restenosis and stent thrombosis – Society for Cardiovascular Angiography and Interventions
Stent angioplasty in coronary artery anomalies with intramural course: when, why, how, with what results?
16 May, 2023 | 14:38h | UTC
Commentary on Twitter
Comprehensive review on #PCI for #CoronaryArteryAnomalies. CAA are associated w cardiac death in select patients w ectopic origins. Acute ischemia may be seen in young athletes & #PCI may be appropriate in select patients.
➡️ https://t.co/j4ELX7jZxp @SarasVallabhMD @RizikMd pic.twitter.com/fHSXeIftcU
— MyJSCAI (@MyJSCAI) May 2, 2023
Review | Dilemmas in cardiology: when to recanalize a chronic total occlusion
12 May, 2023 | 13:19h | UTCSee all articles in the series here
M-A | PCI vs. CABG in non–ST-elevation coronary syndromes and multivessel disease
10 May, 2023 | 15:35h | UTC
Expert Panel | Appropriate use criteria for the management of aortic stenosis
5 May, 2023 | 15:22h | UTC
Contemporary percutaneous management of coronary calcification: current status and future directions
18 Apr, 2023 | 13:06h | UTC
Single arm trial | Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography
12 Apr, 2023 | 13:06h | UTC
RCT | Routine invasive approach fails to benefit frail older adults with non–ST-segment elevation acute myocardial infarction
6 Apr, 2023 | 13:23h | UTCEffect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non–ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
Commentary on Twitter
A routine invasive strategy did not improve clinical outcomes in frail patients with NSTEMI. Future trials should confirm whether a policy of watchful observation rather than routine invasive management may be effective for these patients. https://t.co/N4hAXg5fid
— JAMA Internal Medicine (@JAMAInternalMed) March 6, 2023
Review | Computed tomographic angiography in coronary artery disease
5 Apr, 2023 | 13:33h | UTCComputed tomographic angiography in coronary artery disease – EuroIntervention
SCAI/HRS Expert consensus statement on transcatheter left atrial appendage closure
31 Mar, 2023 | 13:44h | UTCSCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure – JSCAI
Key Points: Consensus Statement on Transcatheter LA Appendage Closure – American College of Cardiology
Commentaries:
SCAI/HRS Consensus Document Covers the Ins and Outs of LAAO – TCTMD
RCT | 3-6 month DAPT noninferior to 12 month DAPT in patients undergoing PCI with third-generation DES
22 Mar, 2023 | 13:29h | UTCSummary: In a randomized trial involving 2,013 patients across 37 centers in South Korea, researchers compared the effectiveness of 3-6 month dual antiplatelet therapy (DAPT) versus 12 months of DAPT after percutaneous coronary intervention (PCI) using third-generation drug-eluting stents.
The primary outcome was net adverse clinical events (NACE), a composite of cardiac death, target vessel myocardial infarction, clinically driven target lesion revascularization, stent thrombosis, or major bleeding.
The study found that 3-6 month DAPT was non-inferior to 12-month DAPT for NACE (3.7% vs. 4.1%, respectively), with a consistent treatment effect across various subgroups. No significant differences were observed in target lesion failure or major bleeding between the two groups.
Despite these findings, further research is needed to generalize the results to other populations and to determine the ideal regimen for 3-6 month DAPT.
Article: Comparison Of 3-6 Month Versus 12 Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial – Circulation (link to abstract – $ for full-text)
Commentary: Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA – TCTMD
Related:
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial – JAMA Cardiology (link to abstract – $ for full-text)
Commentary on Twitter
#OriginalResearch simpub #CircACC23: The HOST-IDEA RCT showed DAPT duration of 3-6mo was non-inferior to 12mo for net adverse clinical events in patients undergoing PCI with 3rd-gen DES @drlsj https://t.co/uD8RKc03Ci pic.twitter.com/DXPvoyiNke
— Circulation (@CircAHA) March 5, 2023
RCT | A 10-y comparison of paclitaxel-coated balloon, paclitaxel-eluting stent, and plain balloon angioplasty for DES in-stent restenosis
20 Mar, 2023 | 13:42h | UTCSummary: The ISAR-DESIRE 3 trial aimed to compare the 10-year efficacy and safety of plain balloon (PB), paclitaxel-coated balloon (PCB), and paclitaxel-eluting stent (PES) for percutaneous coronary intervention (PCI) of drug-eluting stent (DES) in-stent restenosis (ISR).
A total of 402 patients with DES-ISR were randomized to the different treatment groups: 134 patients to PB angioplasty (160 lesions), 137 patients to PCB angioplasty (172 lesions), and 131 patients to PES implantation (168 lesions).
PCB angioplasty and PES implantation had comparable 10-year results in the device-oriented composite endpoint including cardiac death, target vessel myocardial infarction, target lesion thrombosis, or target lesion revascularization, and significantly reduced the incidence of repeat target lesion revascularization compared to PB angioplasty alone. However, an excess of mortality within 5 years associated with PES warrants further investigation.
Article: Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial – European Heart Journal (free for a limited period)
Commentary on Twitter
Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial 👉https://t.co/NHQpCIaNod #EHJ #ESCYoung @ehj_ed @rladeiraslopes
— European Society of Cardiology Journals (@ESC_Journals) March 8, 2023
Review | Transcatheter interventions for heart failure
17 Mar, 2023 | 12:44h | UTCTranscatheter interventions for heart failure – EuroIntervention
RCT | Three-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis
14 Mar, 2023 | 13:47h | UTCThree-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis – Journal of the American College of Cardiology (link to abstract – $ for full-text)
News Release: Benefits of TAVR Remain Consistent in Patients at Low Surgical Risk at Three Years – American College of Cardiology
Commentary on Twitter
#ACC23/#WCCardio #JACC LBCT SimPub: Data from the Evolut Low Risk trial demonstrated that #TAVR at 3 years showed durable benefits compared with surgery with respect to all-cause mortality or disabling stroke. https://t.co/PtEEFI1P1t#vhdAS #SAVR #CardioTwitter @kashishgoelmd pic.twitter.com/x0milxBGxO
— JACC Journals (@JACCJournals) March 5, 2023